For Investors

Late-Stage AMD is the Leading Cause of Blindness in Older Americans1

At Samsara Vision, our novel telescope technology combined with our patient support program provides health care providers with an important option to treat their most visually impaired patients living with late-stage AMD. We’re also invested in creating next-generation devices and delivery systems that will improve the surgical experience for both the provider and the patient. Our goal is to help the late-stage AMD patient population gain access to technology that is proven to improve their quality of life and extend the freedom they have to reengage in the activities that are most important to them.

Market Opportunity:

  • A 2017 study published in JAMA Ophthalmology by Neely and colleagues revealed that a large number of AMD cases go undetected and undiagnosed in the primary eye care setting.2
  • As many as 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050.3
  • A study published in The Lancet projects that the number of people worldwide with AMD will grow from 196 million in 2020 to 288 million in 2040.4 AMD is the leading cause of irreversible visual loss in the United States, with variable degrees of age-related macular changes occurring in more than 10% of the population aged 65-74 years and 25% of the population older than 74 years.5 6 7

1. Age-related Macular Degeneration. National Eye Institute.
2. Neely DC, Bray KJ, Huisingh CE, Clark ME, McGwin G, Owsley C. Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care. JAMA Ophthalmol. 2017;135(6):570–575. doi:10.1001/jamaophthalmol.2017.0830
3. National Institutes of Health, National Eye Institute. Prevalence of Blindness** Data--Data Tables, Summary of Eye Disease Prevalence Data: “Prevalence of Cataract, Age-Related Macular Degeneration, and Open-Angle Glaucoma Among Adults 40 Years and Older in the United States” Archives of Ophthalmology, Volume 122, April 2004;
4. Wan Ling Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Cheng, Tien Yin Wong, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, The Lancet Global Health, Volume 2, Issue 2, 2014, Pages e106-e116, ISSN 2214-109X,
5. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003; 121(11):1621-4 (ISSN: 0003-9950)
6. The Eye Diseases Prevalence Research Group*. Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572. doi:10.1001/archopht.122.4.564
7. Age Related Macular Degeneration Data and Statistics. NEI. NIH. Last updated July 2019.